ArticleAnnals of neurosciences2026
Experience with Tenecteplase in Treatment of Acute Ischaemic Stroke in Window: Analysis and Outcomes at a Tertiary Care Institute in Central India.
Article in Annals of neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intravenous thrombolysis with alteplase has been the standard for acute ischaemic stroke (AIS) within 4.5 h, but tenecteplase (TNK) is gaining promising corner in intravenous thrombolysis with some unique features and superior efficacy in large vessel occlusion (LVO). Purpose: This study evaluates real-world TNK outcomes at a Central Indian tertiary centre. Methods: This ambispective single-centre study included 36 AIS patients presenting within <4.5 h of onset, meeting inclusion criteria (age >18 years, National Institutes of Health Stroke Scale (NIHSS)-assessed, blood pressure <185/110 mmHg, no contraindications). Weight-based TNK (0.25 mg/kg bolus) was administered. NIHSS was noted at admission, 48 h, 7 days and discharge; modified Rankin Scale at discharge and at 90 days was also recorded. Demographics, comorbidities, vessel angiography status and complications were analysed using descriptive statistics and Results: The mean age was 57.67 ± 14.32 years, and 75% of patients were males. Hypertension (61.1%) and smoking (30.6%) were the predominant comorbidities. Mild stroke (NIHSS 1-5) occurred in 58.33% of cases, and LVOs were present in 27.78% (bilateral internal carotid artery (ICA) in 13.89%, middle cerebral artery M1/M2 in 13.89%). Patients with bilateral ICA occlusions experienced a mean NIHSS reduction of 6 points, compared to 3.5 points in others ( Conclusion: TNK use had robust success in lowering NIHSS scores, particularly in LVOs, with excellent safety, being a single bolus, more cost-effective, no time wastage for infusion preparation supporting its preference over standard alteplase. TNK may be a better choice in resource-limited set-up. Multicentre trials are needed for its widespread adoption and also for its conjunctive use with mechanical thrombectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.